Centaurus Financial’s Zevra Therapeutics ZVRA Stock Holding History

Centaurus Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-156	Closed	-$16K	–	2085
2018 Q2	$16K	Buy	+156	New	+$15.2K	﹤0.01%	1381

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Centaurus Financial's ZVRA Position: Q3 2018 in Review

Centaurus Financial sold out of Zevra Therapeutics (ZVRA) in Q3 2018, closing a stake of 156 shares — an estimated $16K sold.

Centaurus Financial first reported a position in ZVRA in Q2 2018 and held it in 1 quarter. The position peaked at $16K in Q2 2018. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2018.

Centaurus Financial reported no remaining Zevra Therapeutics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 156 Zevra Therapeutics shares in Q3 2018, an estimated $16K.
Centaurus Financial first reported a position in Zevra Therapeutics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Zevra Therapeutics position peaked at $16K in Q2 2018.
33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.